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HEALTH POLICY—Healthcare Reimbursement
Studies
PHP1
ASSESSMENT OF PROPOSED GUIDELINES FOR
PHARMACOECONOMIC SUBMISSIONS IN
GREECE: OVERVIEW AND IMPLEMENTATION
PROBLEMS
Geitona M1, Karokis A2,Vandoros C3, Karamalis M4
1National School of Public Health, Athens, Greece;
2AstraZeneca SA, Maroussi, Greece; 3Janssen-Cilag
Pharmaceutical S.A.C.I, Pefki, Greece; 4Novo Nordisk A/S,
Vouliagmeni, Greece
OBJECTIVES: Greek authorities have proposed draft
pharmacoeconomic (PE) guidelines for reimbursement
submissions. Our objective is to compare these to guide-
line documents in the EU countries, Australia and Canada
in terms of purpose and methodology and identify poten-
tial implementation problems. METHODS: We reviewed
and compared the proposed guidelines along the follow-
ing criteria: purpose of PE analysis, responsibility and
conduct, type of analysis, comparator choice, perspective,
resource use and cost assessment, outcome measurement
and validation of results. Based on the above as well as
current Greek literature we assessed potential problems
in implementing the proposed guidelines. RESULTS: In
terms of comparison, pharmacoeconomic submissions in
Greece aim at reimbursement. PE studies can be con-
ducted either by the pharmaceutical industry, CROs or
academia. Cost-minimization analysis is sufﬁcient when
effectiveness of the alternatives is equal. Otherwise, cost
consequence analysis is mandatory followed by cost-
effectiveness, cost-beneﬁt or cost-utility analyses. Stan-
dard and least costly existing therapies are mandatory
comparators. The perspective of analysis is not clearly
stated. Cost outcomes should reﬂect detailed resource use
description. Effectiveness measures should be based on
RCTs or meta-analysis results. No explicit reference is
made of naturalistic studies. Modeling is accepted. QoL
outcomes are accepted. Discounting and sensitivity analy-
ses are obligatory. As a result of our comparative analy-
sis, the following issues should be investigated in the
transition phase. Applying monetary values is difﬁcult
given the absence of ofﬁcial price lists and concurrent use
of public and private providers. Epidemiological data and
databases regarding clinical practice are scant. Extensive
modeling assumptions are required to transfer interna-
tional clinical data to the Greek environment. Experience
with PE is rare among researchers and government.
CONCLUSIONS: Proposed guidelines are similar with
published ones, with minor country-speciﬁc differences.
The implementation problems identiﬁed require a transi-
tion phase to establish methodological grounds and gen-
erate experience.
PHP2
VARIABILITY IN EUROPEAN REIMBURSEMENT
SCHEMES FOR ANTIBIOTICS: CONSEQUENCES
FOR EUROPEAN SURVEILLANCE OF
ANTIBIOTIC CONSUMPTION (ESAC PROJECT)
Ferech M, Elseviers MM,Vander Stichele RH, Goossens H
University of Antwerp, Wilrijk-Antwerp, Belgium
OBJECTIVE: The ESAC project is funded by the Euro-
pean Commission to collect reliable and comparable data
on antibiotic consumption in all European countries. The
aim of this study is to identify the reimbursement status
of antimicrobials in participating countries and to assess
its impact on the comparability of utilization data col-
lected in national databases. METHODS: A structured
questionnaire was sent to national representatives in all
participating EU and applicant countries and obtained
data were validated by comprehensive literature search.
We limited this pilot analysis to reimbursement rules for
uncomplicated acute infection in adult persons (econom-
ically active), as co-payment schemes often vary widely,
depending on health and social status of patient.
RESULTS: Thirty countries participated. Two axes of 
differentiation were discovered in the reimbursement
systems. Firstly, the axis of homogeneity: is the reim-
bursement rate ﬁxed and identical across and among
antibiotic classes or not? Secondly the axis of initial
private payment: is the reimbursement system without
limitations or does the reimbursement start only above a
ﬁxed threshold co-payment (prescription cap) or a thresh-
old co-payment for multiple prescriptions over a given
period? Homogeneity without threshold co-payment was
observed most frequently (n = 13). Homogeneity, with
threshold co-payment was observed in eight countries. In
the remaining nine countries reimbursement status differs
across antibiotic classes, without reimbursement limita-
tion in six countries, with threshold co-payment in three
countries. CONCLUSIONS: In many European coun-
tries, claims databases based on dispensed reimbursed
medication sufﬁce to record antibiotic usage in a valid
way, as all antibiotics are to some extent reimbursed. In
the other countries, where not all antibiotics are reim-
bursed and/or where reimbursement starts only above a
threshold co-payment, data from claims databases will
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not reﬂect the actual level of utilization and need to be
completed with alternative methods of data collection.
PHP3
IMPROVING PATIENT ACCESS TO
INNOVATION—THE NEW BELGIAN
REIMBURSEMENT PROCEDURE
Umbach I, Quaetaert M,Vannecke C, Dewitte M,
Ravelingien I,Verpooten G, Tomas M
NIHISB, Brussels, Belgium
OBJECTIVES: Belgium has implemented since January
2002 a new reimbursement structure—the Commission
for the Reimbursement of Medicines (CRM). One of the
objectives is to improve time taken between the granting
of a marketing authorisation and pricing/reimbursement
decisions in full consistency with the European Commu-
nity legislation. METHODS: The CRM is responsible for
both clinical and economic evaluation of the submissions.
The decision relating to the admission of a specialty to
the list of reimbursed products is taken after evaluation
of several criteria: therapeutic value, price and basis for
reimbursement, therapeutic and social needs, budget
impact and cost-effectiveness. With regard to the thera-
peutic value, three classes have been deﬁned: class 1)
demonstrated added value; class 2) no added value; and
class 3) generic drugs. For an independent evaluation of
the dossiers the NIHISB has appointed a team of internal
experts. They provide evaluation reports within 60 days
and a reimburserment proposal within 150 days, to be
endorsed by the CRM. Guidelines have been developed
to assist applicants in preparing their submissions.
RESULTS: From January 1st to June 1st, 2002, 219
dossiers have been submitted to the CRM. Seventy-one
evaluation reports were issued during the same period
and timeline compliance was >90%. CONCLUSIONS:
After ﬁve months of CRM functioning, the timelines are
respected and a large majority of the evaluation reports
produced by the internal experts were endorsed. The
main challenges for the future will be to keep trans-
parency and consistency in the decisions taken, to respect
the short deadlines, to maintain the independence of mind
of the experts, and to continue to evaluate sequentially
the scientiﬁc and ﬁnancial aspects in the decision making
process.
PHP4
OUT-OF-POCKET PAYMENT IN BELGIUM:AN
ANALYSIS IN RELATION TO PATHOLOGY
Ooms D, Puttevils D,Wissels G, Koen P, Dirk C,
Beeckmans J
Free University Brussels, Brussels, Belgium
OBJECTIVES: Although mainly ﬁnanced by public
resources, Belgian patients are in most cases bound to pay
a contribution for medical acts and services described in
a very precise nomenclature. In order to lower the burden
of health care costs, the minister of social affairs recently
restricted this patients’ contribution to a maximum
(regarding the nomenclature and lump sum fees), accord-
ing to the ﬁnancial resources of the beneﬁciary. The goal
of this study is to detect elements that force the level out-
of-pocket payment up so that government actions can
take these results into account. METHODS: A represen-
tative sample of 30 acute hospitals (277.521 inpatient
stays) related to data on utilisation of resources and data
concerning the pathology, was withdrawn from national
databank (1996). Using descriptive statistics the patients’
contributions were mapped. Patients with high personal
contributions were selected and analysed. RESULTS:
On average 17% of the total invoice for a hospital stay
is paid by the patients’ own resources (€198,79). This
amount consists of lump sum fees (60,1%), either paid
per admission (medical imaging, technical procedures,
etc.) or depending on the length of stay, not reimbursed
drugs (14,4%), medical acts and services as described in
the nomenclature (11,3%), supplements for medical
devices (7,4%), various costs (6,7%) and clinical biology
(0,1%). Certain patients groups, depending on the
pathology, bear a signiﬁcant larger personal contribution.
CONCLUSIONS: The “maximum invoice” does not fully
cover all out-of-pocket payments. These ﬁndings may
lead to further discussion considering criteria for the
“maximum invoice”.
PHP5
“AUT IDEM”—250 MILLION € SAVINGS P.A.
FOR STATUARY HEALTH INSURANCE IN
GERMANY?
Pirk O, Rosenfeld S, Hass B, Fricke FU
Fricke & Pirk GmbH, Nuremberg, Germany
OBJECTIVE: According to a law recently enacted in
Germany “aut idem” is an imprint on the prescription
obliging the pharmacist to give the patient a drug out of
a group of its cheapest generic versions, unless the physi-
cian excludes this by marking “nec aut idem” on the 
prescription. In view of the Statuary Health Insurance
spendings on pharmaceuticals the Ministry of Health thus
intends to achieve savings of €250 million p. a. but doubts
are manifold. To analyse the efﬁciency of “aut idem” a
model calculation was made for epilepsy treatment.
METHOD: In a decision tree model the costs of “aut
idem” versus “nec aut idem” prescription of Carba-
mazepin were calculated. “Nec aut idem” brings no
change for the patient whereas “aut idem” effects a drug
switch with multiple risks for the patients. On the basis
of up-to-date literature and ofﬁcial data sources assump-
tions were made on the reduction of drug efﬁcacy due to
modiﬁed bioavailability, a risk for 15% of the patients,
with additional ﬁts leading to an increase in treatment
expenses of which only the costs for the patients’ 
social health insurance were taken into consideration.
RESULTS: The What-if-analysis gives proof that in the
ratio of €114,93 to €56,18 “aut idem” is more expensive
